Global Urinary Tract Infection Treatment Market 2017-2021

  • ID: 4372305
  • Report
  • Region: Global
  • 78 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Achaogen
  • Aquinox Pharmaceuticals
  • Bayer
  • Lipella Pharmaceuticals
  • Merck
  • Mylan
  • MORE
About Urinary Tract Infection Treatment

UTI is an infection occurred in any part of the urinary system. The infection mostly involves the lower part of the urinary tract. UTI can be classified into different types depending on the portion of the urinary system affected. Women are comparatively at a higher risk of developing UTI as compared with men since the urethra of the women is comparatively smaller than men and is also closer to the anus. This anatomical structure of the urinary tract in women increases the chances of transfer of the bacteria to the bladder. However, people of any sex and age can get affected by the disease.

The analysts forecast the global urinary tract infection treatment market to grow at a CAGR of 2.15% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global urinary tract infection treatment market for 2017-2021. To calculate the market size, the report considers the sales of branded, off-label, and generic drugs.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
The report, Global Urinary Tract Infection Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Merck,
  • Bayer,
  • Johnson & Johnson,
  • Novartis
Other prominent vendors
  • Achaogen
  • Allergan
  • Aquinox Pharmaceuticals
  • AstraZeneca
  • Lipella Pharmaceuticals
  • MediciNova
  • MerLion Pharma
  • Mylan
  • Novo Nordisk
  • Shionogi
  • Sun Pharmaceuticals
  • Teva Pharmaceutical Industries
  • Urigen
  • Zavante Therapeutics
Market drivers
  • Relation of UTI with several other factors leading to rising incidence rate of UTI
  • For a full, detailed list, view the full report
Market challenges
  • Development of antibacterial resistance
  • For a full, detailed list, view the full report
Market trends
  • Growing awareness of controlled usage of antibiotics
  • For a full, detailed list, view the full report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Achaogen
  • Aquinox Pharmaceuticals
  • Bayer
  • Lipella Pharmaceuticals
  • Merck
  • Mylan
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
  • Market outline
PART 05: Market landscape
  • Market overview
  • Market size and forecast
  • Five forces analysis
PART 06: Pipeline analysis

PART 07: Market segmentation by disease type
  • Uncomplicated UTI
  • Complicated UTI
PART 08: Geographical segmentation
  • UTI treatment market in Americas
  • UTI treatment market in EMEA
  • UTI treatment market in APAC
PART 09: Decision framework

PART 10: Drivers and challenges
  • Market drivers
  • Market challenges
PART 11: Market trends
  • Growing awareness of controlled usage of antibiotics
  • Rising R&D for effective treatment against superbugs/MDR microorganisms
  • Advent of new therapies for UTI treatment
PART 12: Vendor landscape

PART 13: Key vendor analysis
  • Bayer
  • Johnson & Johnson
  • Merck
  • Novartis
  • Other prominent vendors
PART 14: Appendix
  • List of abbreviations
List of Exhibits
Exhibit 01: UTI in various parts of the urinary tract
Exhibit 02: Symptoms, diagnosis, and treatment of UTI
Exhibit 03: Common medications used for the treatment of UTI
Exhibit 04: Global UTI treatment market snapshot
Exhibit 05: Global UTI treatment market 2016-2021 ($ millions)
Exhibit 06: Opportunity analysis of global UTI treatment market
Exhibit 07: Five forces analysis
Exhibit 08: Key pipeline molecules by vendors
Exhibit 09: Global UTI treatment market: Key clinical trials
Exhibit 10: Segmentation of global UTI treatment market by disease type 2016
Exhibit 11: Causative organisms for uncomplicated UTI
Exhibit 12: Global uncomplicated UTI treatment market 2016-2021 ($ millions)
Exhibit 13: Risk factors for uncomplicated UTI
Exhibit 14: Management of uncomplicated UTI through antimicrobial agents
Exhibit 15: Causative organisms for complicated UTI
Exhibit 16: Global complicated UTI treatment market 2016-2021 ($ millions)
Exhibit 17: Risk factors for complicated UTI
Exhibit 18: Segmentation of global UTI treatment market based on geography 2016 and 2021
Exhibit 19: Global UTI treatment market revenue by geography 2016-2021 ($ millions)
Exhibit 20: Market scenario in Americas
Exhibit 21: UTI treatment market in Americas 2016-2021 ($ millions)
Exhibit 22: Market scenario in EMEA
Exhibit 23: UTI treatment market in EMEA 2016-2021 ($ millions)
Exhibit 24: Market scenario in APAC
Exhibit 25: UTI treatment market in APAC 2016-2021 ($ millions)
Exhibit 26: Major factors contributing to UTI
Exhibit 27: New cases of diabetes by 2040
Exhibit 28: Accepted indications for catheter use
Exhibit 29: Major causes of antibiotic resistance
Exhibit 30: Competitive structure analysis of global UTI treatment market 2016
Exhibit 31: Bayer: Key highlights
Exhibit 32: Bayer: Strength assessment
Exhibit 33: Bayer: Strategy assessment
Exhibit 34: Bayer: Opportunity assessment
Exhibit 35: Johnson & Johnson: Key highlights
Exhibit 36: Johnson & Johnson: Strength assessment
Exhibit 37: Johnson & Johnson: Strategy assessment
Exhibit 38: Johnson & Johnson: Opportunity assessment
Exhibit 39: Merck: Key highlights
Exhibit 40: Merck: Strength assessment
Exhibit 41: Merck: Strategy assessment
Exhibit 42: Merck: Opportunity assessment
Exhibit 43: Novartis: Key highlights
Exhibit 44: Novartis: Strength assessment
Exhibit 45: Novartis: Strategy assessment
Exhibit 46: Novartis: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Achaogen
  • Aquinox Pharmaceuticals
  • Bayer
  • Lipella Pharmaceuticals
  • Merck
  • Mylan
  • MORE
New Report Released: - Global Urinary Tract Infection Treatment Market 2017-2021

The author of the report recognizes the following companies as the key players in the global urinary tract infection treatment market: Merck, Bayer, Johnson & Johnson, Novartis.

Other Prominent Vendors in the market are: Achaogen, Allergan, Aquinox Pharmaceuticals, AstraZeneca, Lipella Pharmaceuticals, MediciNova, MerLion Pharma, Mylan, Novo Nordisk, Shionogi, Sun Pharmaceuticals, Teva Pharmaceutical Industries, Urigen, and Zavante Therapeutics.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is Growing awareness of controlled usage of antibiotics. Antibiotic resistance is one of the major problem being faced by the medical world today. Antibiotic resistance can be defined as a term when a microorganism changes itself and remains no longer sensitive to that particular antibiotic. In this condition, the antibiotic is no longer capable of killing or inhibiting the growth of the bacteria.”

According to the report, one of the major drivers for this market is Relation of UTI with several other factors leading to rising incidence rate of UTI. Interconnection of UTI with other healthcare conditions and changing lifestyle habits have led to the rising incidence of the disease. This, in turn, is expected to rise the demand for the treatment facilities for the UTI. The disease is more common in women as compared with men. Around 50% of the women globally have chances of developing UTI at least once in their lifetime. This accounts for a large population and demands huge attention. Apart from gender, many other factors such as obesity and diabetes contribute to the rising incidence of UTI.

Further, the report states that one of the major factors hindering the growth of this market is Development of antibacterial resistance. UTI is primarily a bacterial infection. The development of antibacterial resistance organisms is a huge challenge for the global UTI treatment market. MDR microorganisms make the UTI more severe. MDR microorganisms are the species of organisms that exhibit resistance to several antimicrobial drugs. It may consist of viruses, fungi, bacteria, and several other parasites. MDR bacteria are considered as the most threatening group among all these organisms as they have shown significant impact on the public health.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Merck
  • Bayer
  • Johnson & Johnson
  • Novartis
  • Achaogen
  • Allergan
  • Aquinox Pharmaceuticals
  • AstraZeneca
  • Lipella Pharmaceuticals
  • MediciNova
  • MerLion Pharma
  • Mylan
  • Novo Nordisk
  • Shionogi
  • Sun Pharmaceuticals
  • Teva Pharmaceutical Industries
  • Urigen
  • Zavante Therapeutics
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll